Is AOD-9604 Legal in Oregon? How to Access It Legally

What Is AOD-9604 and Why Does Its Legal Status Matter?

AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone (hGH), specifically residues 177 through 191. Researchers designed it to retain hGH's lipolytic properties while eliminating the growth-promoting and insulin-desensitizing effects tied to IGF-1 stimulation. Because it does not measurably raise IGF-1 in clinical doses, it avoids the adverse-effect profile that limits long-term hGH therapy for weight management.

The legal status matters because Oregon residents and their clinicians need to know exactly which regulatory rules apply before prescribing, dispensing, or purchasing the peptide. The rules that govern AOD-9604 are federal first, state second, and they are not simple.

The Science Behind the Peptide

AOD-9604 binds beta-3 adrenergic receptors and stimulates lipolysis in adipocytes without activating the GH receptor pathway that drives IGF-1 production. A randomized, double-blind, placebo-controlled Phase IIb trial published in the International Journal of Obesity (N=300) demonstrated statistically significant fat loss at oral doses of 1 mg/kg/day over 12 weeks compared with placebo (P<0.001) [1]. Subcutaneous formulations used in peptide clinics today typically range from 250 mcg to 500 mcg per injection, once daily, though no subcutaneous dose has received FDA approval.

Why Approval Status Shapes Everything

FDA approval determines which distribution channels are lawful. Because AOD-9604 has never received New Drug Application (NDA) approval for any indication in the United States, it cannot be sold as a finished pharmaceutical product [2]. That single fact cascades into every access question Oregon patients ask.

Federal Regulatory Framework: Where AOD-9604 Actually Stands

The FDA does not maintain a simple "approved or banned" binary for compounded substances. Instead, it operates a tiered system that directly controls whether a compounding pharmacy can legally prepare AOD-9604 for a specific patient.

The 503A Bulk Substances List

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows state-licensed pharmacies to compound drugs for individual patients from bulk active pharmaceutical ingredients (APIs), but only when those bulk substances appear on an FDA-approved list, have a USP monograph, or are otherwise not prohibited [3]. The FDA publishes a Bulk Drug Substances Nominated for Use in Compounding Under Section 503A list. AOD-9604 was nominated for this list. As of the most recent update, the FDA has categorized AOD-9604 in the group of substances "under evaluation," meaning it has not been placed on Category 1 (nominated and appropriate for compounding) but has also not been placed on the prohibited list [4].

This "under evaluation" status is the core of the gray zone. Pharmacies that compound AOD-9604 do so in a legally uncertain environment. The FDA has not issued an enforcement letter specifically banning 503A compounding of AOD-9604, but it has signaled that substances remaining unresolved carry compounding risk.

The 503B Outsourcing Facility Distinction

Section 503B of the FD&C Act covers outsourcing facilities, which compound larger batches without individual patient prescriptions [5]. AOD-9604 is not on the FDA's 503B bulk drug substances list for outsourcing facilities. This means a 503B facility cannot legally produce AOD-9604 for distribution to clinics or hospitals. Any clinic receiving AOD-9604 from a 503B facility is operating outside current FDA guidance.

FDA Enforcement Posture on Peptides

The FDA's 2022 guidance document on bulk drug substances in compounding noted heightened scrutiny for peptides that lack adequate safety and efficacy data [6]. AOD-9604's developer, Metabolic Pharmaceuticals Ltd., obtained Generally Recognized As Safe (GRAS) status from the FDA for AOD-9604 as a food ingredient in 2014 [7]. That GRAS designation applies to oral ingestion as a food additive and does not confer drug approval or support injectable compounding. Clinicians sometimes cite the GRAS status as evidence of safety, which is accurate in a narrow sense, but it does not resolve the compounding legality question.

Oregon State Law: What the State Adds (and Does Not Add)

Oregon does not have a separate statute that independently legalizes or bans AOD-9604. State-level pharmacy law in Oregon, governed by the Oregon State Board of Pharmacy (OSBP) under ORS Chapter 689, generally tracks federal compounding rules [8]. The OSBP requires that compounding pharmacies operating in Oregon hold appropriate licensure and comply with federal USP standards, including USP <797> for sterile preparations, which applies to injectable peptide formulations.

Oregon Medical Practice Act Considerations

Oregon's Medical Practice Act (ORS Chapter 677) permits licensed physicians, naturopathic physicians, and nurse practitioners with prescriptive authority to prescribe compounded medications when a commercially available alternative does not meet a patient's clinical needs [9]. Because no FDA-approved finished-drug version of AOD-9604 exists, a prescriber can document medical necessity for the compounded form. This documentation requirement is not a formality. The OSBP and Oregon Medical Board can review prescribing patterns for compounded substances, and prescribers who cannot demonstrate individualized clinical rationale face disciplinary exposure.

Naturopathic Prescribers in Oregon

Oregon is one of a small number of states that grants naturopathic physicians (NDs) broad prescriptive authority, including the ability to prescribe compounded medications [10]. Oregon-licensed NDs can therefore prescribe AOD-9604 as a compounded preparation, subject to the same documentation requirements as MDs and DOs. This matters practically because a meaningful share of peptide therapy in Oregon flows through naturopathic clinics.

The Research-Chemical Loophole: Why It Is Not a Legal Path

Vendors selling AOD-9604 labeled "for research use only, not for human use" operate in a space that the FDA treats as a misbranding and adulteration violation when the vendor knows or reasonably should know the substance will be used in humans [11]. Oregon residents who purchase AOD-9604 through this channel have no legal protection. The substance is not tracked or regulated for purity, sterility, or concentration accuracy. Independent laboratory testing of research-chemical peptides has found significant variation in actual peptide content and contamination with bacterial endotoxins [12]. For a subcutaneous injectable, endotoxin contamination carries direct sepsis risk.

How to Access AOD-9604 Legally in Oregon

Legal access follows a straightforward three-step sequence: a clinical evaluation, a valid prescription, and dispensing through a compliant 503A compounding pharmacy.

Step 1: Clinical Evaluation by a Licensed Oregon Practitioner

A prescriber must assess whether the patient has a documented clinical indication, typically weight management in the context of obesity (BMI >30) or overweight (BMI >27) with at least one comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The evaluation should include a review of prior weight-loss interventions, current medications, metabolic labs, and any contraindications to peptide therapy. The Endocrine Society's 2023 clinical practice guidelines on obesity pharmacotherapy provide a useful framework for documenting treatment necessity [13].

Baseline labs that most prescribers order include fasting glucose, hemoglobin A1c, a complete metabolic panel, a fasting lipid panel, and IGF-1. Because AOD-9604 does not meaningfully raise IGF-1, the baseline IGF-1 primarily serves to rule out pre-existing GH-axis abnormalities.

Step 2: A Written Prescription

Oregon law requires a valid patient-practitioner relationship before any prescription is issued, including for compounded medications. Telehealth visits with Oregon-licensed providers satisfy this requirement, provided the visit meets the Oregon Health Authority's telemedicine standards [14]. The prescription must specify the compound, strength, volume, route of administration, and quantity. Many prescribers write for 250 mcg subcutaneous injections once daily for 90 days with one refill, though dosing protocols vary by clinic.

Step 3: Dispensing Through a Compliant 503A Pharmacy

The pharmacy must hold an active Oregon pharmacy license or, if operating from another state, an Oregon non-resident pharmacy license. The compounding facility must comply with USP <797> sterility standards for injectable preparations [15]. Patients should confirm that the pharmacy:

• Holds a current National Association of Boards of Pharmacy (NABP) Verified Pharmacy Program (VPP) credential or equivalent third-party sterility accreditation
• Provides a certificate of analysis (CoA) from an independent third-party laboratory for each batch of AOD-9604
• Does not dispense AOD-9604 without an individual patient prescription (which would indicate 503B-style bulk distribution, currently not permitted for this substance)

The HealthRX clinical team has identified three categories of Oregon patients most likely to receive a compliant AOD-9604 prescription: adults with obesity who have not achieved adequate response to first-line agents like orlistat or metformin, patients who are poor candidates for GLP-1 receptor agonists due to gastrointestinal intolerance, and post-bariatric patients seeking adjunctive fat-loss support during weight-loss plateau phases. These categories do not constitute an approved indication but represent the documented clinical rationale patterns most defensible under current Oregon Medical Board standards.

Comparing AOD-9604 to FDA-Approved Weight-Loss Agents

Understanding where AOD-9604 sits relative to approved alternatives helps both prescribers and patients set appropriate expectations. The comparison also clarifies why some clinicians reach for it despite its uncertain regulatory status.

Approved Agents and Their Evidence Base

Semaglutide 2.4 mg (Wegovy) remains the highest-evidence option for chronic weight management. The STEP-1 trial (N=1,961) demonstrated a mean 14.9% reduction in body weight at 68 weeks versus 2.4% with placebo (P<0.001) [16]. Tirzepatide 15 mg (Zepbound) showed even greater weight reduction in SURMOUNT-1 (N=2,539), with a mean 20.9% loss at 72 weeks versus 3.1% placebo (P<0.001) [17].

AOD-9604's Phase IIb data showed significantly more modest effects, approximately 1 to 2 kg of additional fat loss over 12 weeks at optimal doses [1]. No head-to-head trial comparing AOD-9604 to semaglutide or tirzepatide exists. Prescribers who choose AOD-9604 over approved agents need a documented reason, and cost plus GI tolerability are the two most common justifications appearing in clinical notes reviewed by state medical boards.

The IGF-1 Advantage

One specific reason a clinician might prefer AOD-9604 over recombinant hGH for a patient with mild GH deficiency and excess adiposity: AOD-9604 does not stimulate IGF-1. The American Association of Clinical Endocrinology (AACE) 2019 guidelines note that supraphysiologic IGF-1 levels are associated with increased colorectal and breast cancer risk [18]. A patient who wants hGH-like lipolysis without that IGF-1 exposure has at least a coherent rationale for AOD-9604, even if the evidence base is thin.

Monitoring and Safety Considerations for Oregon Patients

No serious adverse events were reported in the Phase IIb trial at doses up to 1 mg/kg/day orally [1]. Injectable subcutaneous formulations have a different absorption profile, and no prospective safety data on subcutaneous AOD-9604 in human subjects has been published in peer-reviewed literature. This absence of data is itself a safety consideration that prescribers must disclose.

What to Monitor

Prescribers following current best-practice patterns typically recheck fasting glucose and IGF-1 at 90 days. A 2021 review in Frontiers in Endocrinology examining peptide safety in clinical practice recommended lipid panel reassessment at 12 weeks for any lipolytic agent given the theoretical risk of transient dyslipidemia during rapid fat mobilization [19]. Injection-site reactions, the most commonly reported adverse effect, are usually mild and self-resolving.

Disclosure Requirements

Oregon's informed-consent standards require that patients understand when a treatment is investigational or lacks FDA approval. Prescribers must document that AOD-9604 is a compounded, non-FDA-approved substance, that its long-term safety in subcutaneous form has not been established in controlled trials, and that alternatives with stronger evidence exist [20]. Skipping this disclosure step creates both ethical and medicolegal exposure for the prescriber.

What Oregon Residents Should Ask Their Provider

A direct conversation with a prospective prescriber should include specific questions. Ask whether the provider can name the compounding pharmacy they use and whether that pharmacy holds third-party sterility accreditation. Ask whether the prescription will be written with an individualized clinical justification in the chart. Ask to see the pharmacy's certificate of analysis for the specific batch dispensed to you.

Providers who cannot answer these questions confidently are unlikely to be operating within a compliant framework. A prescriber who says "you can just order it online and I'll supervise" is describing an arrangement that does not meet Oregon's patient-practitioner relationship or prescription requirements.